Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 69fludarabine phosphate 66Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 48Whole-Body Irradiation 47Tacrolimus 44Busulfan 43Cyclosporine 38Azacitidine 35Methotrexate 28Filgrastim 27Antilymphocyte Serum 27Cytarabine 26Decitabine 23Melphalan 22Radiotherapy 21fludarabine 20venetoclax 16Methylprednisolone 16Cyclosporins 13Cord Blood Stem Cell Transplantation 13Injections 12Granulocyte Colony-Stimulating Factor 12Flow Cytometry 12Specimen Handling 11Etoposide 11Biopsy 11Stem Cell Transplantation 10Sirolimus 10Clofarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelomonocytic, Chronic × tamibarotene × Clear all
NCT06085638 2024-03-07

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡